Rep. Rick W. Allen Sells Abbott Laboratories (NYSE:ABT) Stock

Representative Rick W. Allen (Republican-Georgia) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on June 05th, the Representative disclosed that they had sold between $15,001 and $50,000 in Abbott Laboratories stock on April 16th. The trade occurred in the Representative’s “R.W. ALLEN & ASSOCIATES, INC. > RWA&A – SECURITIES” account.

Representative Rick W. Allen also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Intuit (NASDAQ:INTU) on 4/16/2026.
• Sold $15,001 – $50,000 in shares of Procter & Gamble (NYSE:PG) on 4/16/2026.
• Sold $15,001 – $50,000 in shares of S&P Global (NYSE:SPGI) on 4/16/2026.
• Sold $50,001 – $100,000 in shares of Ameriprise Financial (NYSE:AMP) on 4/15/2026.

Abbott Laboratories Price Performance

NYSE ABT traded up $0.77 during midday trading on Tuesday, hitting $91.27. The company had a trading volume of 14,108,208 shares, compared to its average volume of 11,270,918. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06. The firm has a 50-day moving average price of $92.26 and a 200-day moving average price of $108.64. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $158.97 billion, a PE ratio of 25.57, a P/E/G ratio of 1.51 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the prior year, the company earned $1.09 EPS. Abbott Laboratories’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott secured CE Mark approval for Libre Duo and Libre Duo 10 Day, described as the world’s first dual glucose-ketone sensing technology for people with diabetes. The approval expands Abbott’s diabetes care portfolio and could support future growth in its continuous glucose monitoring business. Article Title
• Positive Sentiment: Goldman Sachs maintained its Buy rating on Abbott Laboratories, which can help reinforce investor confidence after the stock’s recent weakness. Analyst support often matters when sentiment is already focused on valuation and recovery potential. Article Title
• Positive Sentiment: Abbott’s Healthy Food Rx “Food is Medicine” program showed stronger health outcomes when paired with community health worker coaching, including improvements in diabetes management, food insecurity, and physical and mental health. While not a direct earnings driver, it highlights Abbott’s broader healthcare brand and its ability to build programs around chronic disease management. Article Title
• Neutral Sentiment: Abbott was also mentioned in a Motley Fool stock-picking article that called it a “rock-solid” blue-chip name for long-term portfolios. This is broadly supportive of Abbott’s investment image, but it is not company-specific news. Article Title
• Neutral Sentiment: A separate valuation-focused article suggested investors are revisiting whether Abbott is a bargain after its share-price slump. That reinforces the current debate around ABT’s depressed valuation, but it does not add a new catalyst by itself. Article Title
• Negative Sentiment: Abbott remains well below its recent highs and has been under pressure over the past year, so the stock is still trading against a backdrop of weaker longer-term momentum. That context may limit upside until investors see clearer earnings acceleration. Article Title

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Argus reduced their price target on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Evercore dropped their price objective on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Weiss Ratings lowered shares of Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, April 24th. Benchmark lowered their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Finally, Wells Fargo & Company cut their price target on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and an average price target of $119.09.

Institutional Trading of Abbott Laboratories

Hedge funds have recently modified their holdings of the stock. Brighton Jones LLC grew its stake in Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC increased its position in shares of Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after buying an additional 162 shares during the period. United Bank boosted its position in shares of Abbott Laboratories by 7.4% in the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after acquiring an additional 2,001 shares during the period. Main Street Financial Solutions LLC boosted its position in shares of Abbott Laboratories by 13.6% in the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock valued at $1,618,000 after acquiring an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board grew its stake in Abbott Laboratories by 25.6% during the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock valued at $195,267,000 after acquiring an additional 292,547 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau purchased 2,200 shares of the company’s stock in a transaction dated Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The stock was bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.46% of the company’s stock.

About Representative Allen

Rick Allen (Republican Party) is a member of the U.S. House, representing Georgia’s 12th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.

Allen (Republican Party) ran for re-election to the U.S. House to represent Georgia’s 12th Congressional District. He won in the general election on November 5, 2024.

Allen was born in Augusta, Georgia, in 1951. He attended Auburn University in Alabama, graduating in 1973 with a B.S. in building construction.

After earning his degree, Allen worked as an estimator, project administrator and assistant to the president with a construction firm in Augusta. In 1976, he founded his own construction business, R. W. Allen & Associates, Inc. The company operates in six states across the country. In 2008, Allen was presented with the Augusta Metro Chamber of Commerce’s Small Business Person of the Year award.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.